Day 1

Monday, July 1

• Visit of the ARRONAX cyclotron
• Lectures on radio-isotope production and extraction, radiochemistry and dosimetry
• 1 spot on nuclear medicine

• Radionuclide production: means and limitations
  Férid Haddad
  Researcher in Nuclear Physics on production of radionuclides for medical applications, Subatech - Laboratoire de physique subatomique et des technologies associées, Institut National de Physique Nucléaire et de Physique des Particules, Head of GIP ARRONAX

Radionuclides utilized in nuclear medicine are mostly produced artificially by induced nuclear reaction on a target material using different types of projectiles. To produce these projectiles one can use research nuclear reactors for neutrons or accelerators for protons, deuterons, ions, α particles, γ, etc. After the presentation of the overall radionuclide production scheme, we will describe the different production methods using the production of alpha emitters as a guide to enlighten their strengths and limitations.

• Radiolabelling Chemistry
  François Guérard
  Researcher in Medicinal Chemistry, Nuclear Chemistry and Radiochemistry, Nuclear Onclogy group, CRCI²NA

• Dosimetry in targeted radiation therapy: necessary, nice to have, or counterproductive ?

• Internal dosimetry: from theory to practice
  Arnaud Dieudonné
  Medical physicist in Nuclear Medicine, Centre Henri Becquerel, Rouen

While the concept of internal dosimetry dates back several decades, its routine clinical application is relatively recent and has been stimulated by the development of nuclear medicine imaging and new applications of targeted radionuclide therapy (TRT). One TRT modality that has particularly benefited from dosimetry over the last decade is liver radioembolization with Y90-loaded microspheres. New methodological concepts have been developed to better personalize dosimetry and plan treatment. Radiobiological concepts already applied to external beam radiotherapy (EBRT) can now be applied to TRT. This is not only interesting in terms of reconciling the clinical results of the two therapeutic modalities, but can also bring new perspectives to better control treatment outcomes. This conference will provide an overview of internal dosimetry and state-of-the-art protocols for beta emitters

• Targeted alpha therapy dosimetry
  Nicolas Chouin
  Researcher in Medical Physics, Nuclear Onclogy group, CRCI²NA - Oniris Nantes

• Back to ISI NucMed program 2024